4R-Tau Targeting Therapy for PSP

4R-Tau Targeting Therapy for Progressive Supranuclear Palsy

Overview

4R-Tau Targeting Therapy for Progressive Supranuclear Palsy

Overview

4R-Tau Targeting Therapy is a novel therapeutic approach specifically designed for Progressive Supranuclear Palsy (PSP) and other 4R-tauopathies. This therapy targets the selective reduction of the tau isoform containing four microtubule-binding repeats (4R-tau), which is the predominant form driving pathology in PSP.

Therapeutic Rationale

The 4R-Tau Problem in PSP

PSP is characterized by the accumulation of hyperphosphorylated 4R-tau in neurons and glia, particularly in the basal ganglia, subthalamic nucleus, brainstem oculomotor nuclei, and cerebellar dentate nucleus. Unlike Alzheimer's disease where both 3R and 4R tau isoforms are present, PSP is a "pure 4R-tauopathy," meaning therapeutic strategies can be isoform-specific.

Key pathological features:

• 4R-tau filaments form neurofibrillary tangles in subcortical structures
• Neuronal loss in globus pallidus externa and interna
• Subthalamic nucleus degeneration
• Oculomotor nerve palsy due to midbrain involvement
• Falls due to axial rigidity and bradykinesia

Mechanistic Approach

This therapy employs multiple complementary mechanisms to achieve 4R-tau reduction:

10-Dimension Rubric Scoring

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 9 | First-in-class approach targeting isoform-specific mechanism in PSP |
| Mechanistic Rationale | 9 | Strong genetic and biochemical evidence for 4R-tau as primary driver of PSP pathology |
| Root-Cause Coverage | 9 | Addresses the fundamental isoform imbalance rather than downstream effects |
| Delivery Feasibility | 7 | ASO delivery to brain feasible via intrathecal or convective delivery; AAV vectors under development |
| Safety Plausibility | 7 | 3R-tau preservation may reduce off-target effects; requires careful monitoring |
| Combinability | 8 | Synergistic with neuroinflammation modulators, brainstem circuit support, and anti-oxidative stress approaches |
| Biomarker Availability | 8 | CSF 4R-tau/3R-tau ratio available; PET tracers under development |
| De-risking Path | 7 | Can leverage existing tau therapeutic development pathways; need 4R-specific biomarkers |
| Multi-disease Potential | 6 | Primary indication PSP; applicable to CBD, AGD, and other 4R-tauopathies |
| Patient Impact | 9 | Addresses fundamental cause of PSP; high unmet need in this rapidly progressive disorder |

Total Score: 79/100

Disease Coverage Matrix

| Disease | Coverage Score | Rationale |
|---------|----------------|-----------|
| Alzheimer's Disease | 3 | Mixed 3R/4R tauopathy; primary strategy targets 3R+4R |
| Parkinson's Disease | 2 | Not primarily 4R-tau driven |
| ALS | 2 | TDP-43 pathology predominant |
| FTD | 5 | Some FTD cases have 4R-tau; depends on subtype |
| PSP | 10 | Primary indication; strong mechanistic rationale |
| MSA | 3 | Alpha-synuclein pathology predominant |
| Aging | 4 | May have incidental tau pathology |

De-risking Path

Phase 1: Preclinical Validation

• Validate 4R-tau/3R-tau ratio modulation in iPSC-derived neurons from PSP patients
• Test ASO efficacy in tau transgenic models with 4R-tau overexpression
• Establish PK/PD relationship for brain delivery

Phase 2: Safety Assessment

• GLP toxicology in non-human primates
• Monitor for compensatory changes in 3R-tau expression
• Assess immune response to tau-targeting biologics

Phase 3: Clinical Development

• Patient enrichment: Select PSP patients with elevated CSF 4R-tau
• Biomarker-driven dosing based on CSF 4R-tau/3R-tau ratio
• Clinical endpoints: PSP Rating Scale,falls frequency, vertical gaze palsy progression

Key Risk Mitigations

• 3R-tau preservation: Careful dose-finding to avoid complete tau reduction
• Off-target effects: Use isoform-specific promoters and targeting sequences
• Immunogenicity: Humanized antibodies, minimized foreign protein motifs

Combination Therapy Potential

4R-Tau Targeting Therapy is ideally suited for combination approaches:

Evidence Base

Genetic Evidence

• MAPT H1 haplotype associated with increased PSP risk
• Mutations in MAPT exon 10 causing PSP-like phenotypes (splicing mutations)
• Tau gene duplications leading to 4R-tau overexpression

Biochemical Evidence

• Elevated 4R-tau in PSP brain tissue vs. age-matched controls
• 4R-tau specifically enriched in PSP neurofibrillary tangles
• Post-mortem studies show correlation between 4R-tau burden and clinical severity

Preclinical Models

• Transgenic mice with human 4R-tau show PSP-like pathology
• AAV-mediated 4R-tau overexpression in rodents producesNFT-like inclusions
• ASO-mediated exon 10 skipping reduces 4R-tau in preclinical models

Implementation Roadmap

Year 1

• Complete IND-enabling studies for lead ASO candidate
• Establish CSF 4R-tau assay for patient stratification
• Initiate Phase 1 clinical trial in PSP patients

Year 2

• Complete Phase 1 safety assessment
• Initiate biomarker-driven Phase 2 efficacy trial
• Explore AAV-based gene therapy approach

Year 3+

• Pivotal registration trial for PSP
• Expand to other 4R-tauopathies (CBD, AGD)
• Develop oral small-molecule option for chronic dosing

Actionable Next Steps

References